Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Velnacrine SCHEMBL194467 | 0.79 | CYP1A2 (1.00) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL4780466 | 0.77 | ACHE (0.66) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL20402681 | 0.75 | TSHR (0.51) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL3807927 | 0.75 | CYP1A2 (0.72) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL27937060 | 0.73 | ACHE (0.70) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3242591 | 0.73 | TSHR (0.70) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL9547653 | 0.73 | ACHE (1.00) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL9547702 | 0.72 | ACHE (0.97) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| SCHEMBL20720692 | 0.72 | ACHE (0.53) | ACHECYP1A2CYP2C9TSHRALDH1A1 | |
| Velnacrine SCHEMBL637476 | 0.72 | TSHR (0.83) | ACHECYP1A2CYP2C9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0499231-B1 | 9-Aminotetrahydroacridines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5502203-A | FOR ACRIDINE COMPOUNDS USED IN TREATMENT OF ALZHEIMER*S DISEASE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5382594-A | Cognition activators | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0589900-A1 | ALZHEIMER'S DISEASE TREATMENT WITH TACRINE METABOLITES | INSTITUTE OF PSYCHIATRY (GB) | 1994-04-06 | — | — | EP | disclosed |
| US-5210087-A | Cognition Activators | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-05-11 | — | — | US | disclosed |
| WO-1992022534-A1 | ALZHEIMER'S DISEASE TREATMENT WITH TACRINE METABOLITES | MARCHBANKS ROGER MICHAEL (GB) | 1992-12-23 | — | — | WO | disclosed |
| EP-0499231-A1 | 9-Aminotetrahydroacridines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ACHE 16/4885CYP1A2 4587/4885CYP2C9 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.